Protalix BioTherapeutics (PLX) Cash from Financing Activities (2010 - 2026)
Protalix BioTherapeutics' quarterly Cash from Financing Activities came in at $150000.0 in Q1 2026, down 97.04% year-on-year from $5.1 million in Q1 2025, and up 2.74% quarter-over-quarter from $146000.0 in Q4 2025.
Protalix BioTherapeutics has reported Cash from Financing Activities for 15 years, with the latest figure at $150000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 97.04% year-over-year to $150000.0; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (down 49.44% YoY), and the FY2025 full-year result was $9.3 million, up 155.53% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $150000.0, up from $146000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $14.2 million in Q1 2023, with the low at $146000.0 in Q4 2025.
- Average Cash from Financing Activities over 5 years is $4.8 million, with a median of $4.1 million recorded in 2022.
- Year-over-year, Cash from Financing Activities surged 200.72% in 2022 and tumbled 97.04% in 2026.
- Tracing PLX's Cash from Financing Activities over 5 years: stood at $4.1 million in 2022, then jumped by 156.02% to $10.4 million in 2023, then slumped by 65.24% to $3.6 million in 2024, then tumbled by 95.97% to $146000.0 in 2025, then grew by 2.74% to $150000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $150000.0 (Q1 2026), $146000.0 (Q4 2025), and $4.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 150,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 150,000.00 |
| Mar 31, 2026 | 150,000.00 |
| Dec 31, 2025 | 146,000.00 |
| Dec 31, 2025 | 146,000.00 |
| Jun 30, 2025 | 4.10 Mn |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Mar 31, 2025 | 5.08 Mn |
| Dec 31, 2024 | 3.63 Mn |
| Dec 31, 2024 | 3.63 Mn |
| Jun 30, 2023 | 10.43 Mn |
| Jun 30, 2023 | 10.43 Mn |
| Mar 31, 2023 | 14.23 Mn |
| Mar 31, 2023 | 14.23 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Dec 31, 2022 | 4.08 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Dec 31, 2021 | -4.05 Mn |
| Dec 31, 2021 | -4.05 Mn |
| Sep 30, 2021 | -25.99 Mn |
| Sep 30, 2021 | -25.99 Mn |
| Mar 31, 2021 | 42.11 Mn |
| Mar 31, 2021 | 42.11 Mn |
| Dec 31, 2020 | 4.65 Mn |
| Dec 31, 2020 | 4.65 Mn |
| Sep 30, 2020 | 4.47 Mn |
| Sep 30, 2020 | 4.47 Mn |
| Jun 30, 2020 | -1.26 Mn |
| Jun 30, 2020 | -1.26 Mn |
| Mar 31, 2020 | 38.61 Mn |
| Mar 31, 2020 | 38.61 Mn |
| Sep 30, 2017 | 9.54 Mn |
| Sep 30, 2017 | 9.54 Mn |
| Jun 30, 2017 | -4.24 Mn |
| Jun 30, 2017 | -4.24 Mn |
| Mar 31, 2017 | -6.73 Mn |
| Mar 31, 2017 | -6.73 Mn |
| Dec 31, 2016 | 19.70 Mn |
| Dec 31, 2016 | 19.70 Mn |
| Dec 31, 2015 | 6.10 Mn |
| Dec 31, 2015 | 6.10 Mn |
| Mar 31, 2014 | 31,000.00 |
| Mar 31, 2014 | 31,000.00 |
| Dec 31, 2013 | -68,000.00 |
| Dec 31, 2013 | -68,000.00 |
| Sep 30, 2013 | 66.93 Mn |
| Sep 30, 2013 | 66.93 Mn |
| Dec 31, 2012 | 134,000.00 |
| Dec 31, 2012 | 134,000.00 |
| Sep 30, 2012 | -140,000.00 |
| Sep 30, 2012 | -140,000.00 |
| Jun 30, 2012 | 990,000.00 |
| Jun 30, 2012 | 990,000.00 |
| Mar 31, 2012 | 25.57 Mn |
| Mar 31, 2012 | 25.57 Mn |
| Dec 31, 2011 | 14,000.00 |
| Dec 31, 2011 | 14,000.00 |
| Sep 30, 2011 | 4,000.00 |
| Sep 30, 2011 | 4,000.00 |
| Jun 30, 2011 | -27,000.00 |
| Jun 30, 2011 | -27,000.00 |
| Mar 31, 2011 | 20.94 Mn |
| Mar 31, 2011 | 20.94 Mn |
| Dec 31, 2010 | 342,000.00 |
| Dec 31, 2010 | 342,000.00 |
| Sep 30, 2010 | 132,000.00 |
| Sep 30, 2010 | 132,000.00 |